Embecta Corp. — FY2022 Form 10-K
Reporting period: Fiscal year ended September 30, 2022. This is an annual report, not a standalone fourth-quarter report; the filing does not provide a clear standalone Q4 result. Embecta completed its spin-off from BD on April 1, 2022, so FY2022 includes both pre-separation carve-out results and post-separation results. Prior-period figures reflect BD cost allocations and may not be directly comparable with Embecta as an independent company.
Business context
Embecta is a global diabetes medical-device company selling pen needles, syringes, safety injection devices and a diabetes-care app. It reports one operating segment and sells in more than 100 countries. Pen needles generated $912 million, or 81% of FY2022 net revenue. The company is developing an insulin patch pump for people with Type 2 diabetes and a finer-gauge pen needle; neither had been submitted to the FDA for clearance as of the filing.
Financial results and liquidity
| Metric | FY2022 | FY2021 | Change or context |
|---|---|---|---|
| Revenue | $1,129.5 million | $1,165.3 million | Down 3.1%; down 0.5% on a constant-currency basis |
| Gross profit / margin | $774.9 million / 68.6% | $800.4 million / 68.7% | Gross profit down $25.5 million; margin nearly flat |
| Operating income | $309.6 million | $492.0 million | Down $182.4 million |
| Net income | $223.6 million | $414.8 million | Down $191.2 million; diluted EPS $3.89 vs. $7.28 |
| Adjusted EBITDA | $459.9 million | $565.5 million | Down $105.6 million; non-GAAP measure |
| Cash from operations | $412.2 million | $456.3 million | FY2022 benefited from working-capital movements, including receivables factoring |
| Capital expenditures | $23.6 million | $36.8 million | Cash from operations less capital expenditures was approximately $388.6 million, calculated from reported figures |
Operating-income decline reflected higher standalone selling and administrative costs, $58.9 million of impairment charges for abandoned U.S. production-line projects, and $44.7 million of other operating expenses, primarily separation and stand-up costs. FY2022 interest expense was $46.2 million. The effective tax rate was 12.9%, compared with 16.2% in FY2021.
At September 30, 2022, cash and cash equivalents were $330.9 million, current assets $664.7 million and current liabilities $301.0 million. The company also had an undrawn $500 million revolving credit facility. Total principal debt was $1,645.3 million; reported debt carrying value was $1,607.6 million, including current debt. The weighted-average cost of total debt was 5.2%. Debt is secured by substantially all company assets and is subject to financial and operating covenants; Embecta reported compliance at year-end. Total equity was negative $891.4 million, substantially reflecting the separation-related distribution and accounting entries.
Material changes and management commentary
- Revenue fell 3.1%; the company attributed the decrease to foreign-exchange effects, lower volume following exits from certain legacy customer relationships, and, to a lesser extent, unfavorable U.S. sales-deduction estimates. Contract manufacturing revenue that began after separation partially offset the decline.
- Reported gross margin was essentially unchanged. Inflation in raw materials, freight, labor and overhead was partly offset by lower costs, including the absence of prior-year impairment charges recorded in cost of products sold.
- Selling and administrative expense rose $54.5 million, primarily from added headcount and marketing costs to operate as a standalone public company. R&D expense increased $3.6 million to $66.9 million, mainly reflecting investment in new products.
- Operating cash flow included a favorable $122.7 million change in trade receivables. Embecta factored receivables to BD; the company also reported $110.9 million due from BD at year-end. Inventory-building and higher prepaid expenses used cash.
- Management said it had maintained supply despite inflation and supply-chain constraints, in part by increasing inventory. It expected to incur similar stand-up costs in FY2023 and significant costs over coming years to establish its own IT infrastructure. Management also expected higher FY2023 interest expense if benchmark rates continued to rise.
Outlook, risks and contingencies
- The filing gives no quantified revenue, earnings or cash-flow guidance. Growth depends in part on developing and commercializing new products, including the patch pump and finer-gauge needle; regulatory clearance, development success and market acceptance are uncertain.
- Concentration is material: pen needles represented 81% of revenue, and the three largest distributors together represented approximately 40% of worldwide gross sales. Payer access, reimbursement decisions, price competition and lower-cost providers may pressure sales and margins.
- Embecta relies on BD for cannulas under a supply agreement with purchase limits and specified termination provisions. BD also provides transitional services and distribution support; most such services are due to end within two years of separation. The company must transition systems, operations and product branding away from BD, with risks of cost increases or disruption.
- Local separation closings in China, Mexico and Italy were deferred pending regulatory requirements. The filing warns that delays or manufacturing suspensions could affect supply. The tax matters agreement restricts certain corporate actions for two years after separation and may require indemnification if the spin-off’s tax-free treatment is jeopardized.
- Other risks include variable-rate debt exposure, inflation, currency movements, supplier and manufacturing disruptions, regulatory compliance, cybersecurity, and competition from new diabetes treatments or delivery technologies. A 100-basis-point rate change was estimated to affect annualized Term Loan interest expense by $9.5 million.
- No material legal proceedings were reported as of September 30, 2022 or the financial-statement issuance date. The financial statements received an unqualified audit opinion. The auditor did not opine on internal control over financial reporting; Embecta cited the newly public company transition period. Management reported disclosure controls were effective.
Key facts for investors to verify
- Whether FY2023 revenue, margins and cash generation stabilize after currency effects, customer exits and separation-related changes.
- How much operating cash flow is sustainable apart from receivables factoring and other working-capital movements, and how BD-related balances are settled.
- Debt service, covenant headroom and sensitivity to variable interest rates, alongside the availability of the undrawn revolver.
- Progress, regulatory milestones, investment needs and commercial prospects for the patch pump and finer-gauge needle.
- Continuity of cannula supply and completion of the BD service, rebranding and deferred-country transitions without customer or manufacturing disruption.
- Whether distributor and payer concentration, pricing pressure and the 81% pen-needle revenue concentration change over time.